Research and Healthcare in Inflammatory Bowel Diseases (1)

Slides:

Advertisements

Similar presentations

Inflammatory Bowel Disease: Overview

Advertisements

Managing Crohn’s Disease through Nutritional Intervention

Making dementia a European priority Marseille – 17 October 2008 Jean Georges, Executive Director.

Dalia Munoz.  Its an inflammatory bowel disease (IBD) that causes a long- lasting inflammation in your digestive tract.

ADAMOS ADAMOU, MEDICAL ONCOLOGIST MEMBER OF THE EUROPEAN PARLIAMENT.

1 European Health Forum Gastein Lunch Workshop 1 6 October 2005 What do the patients expect from health professionals? Rod Mitchell, Chairman European.

Baumgart, D C The Diagnosis and Treatment of Crohn's Disease and Ulcerative Colitis Dtsch Arztebl Int 2009; 106(8): ; DOI: /arztebl

CHAPTER 19 Inflammatory Bowel Disease Source: Burden of digestive diseases in the United States, NIH Publication No

By: annie cantrell 5th hour

Definition Signs & symptoms Treatment Root of the disease.

STAKEHOLDER WORKSHOP Do we really know how to curve down asthma in Europe: Lessons from national programmes”? “What about the patient?” Martine Puhl Patient.

Welcome to Newly Diagnosed Night!. Overview Explanation of IBD Review of GI System Differences between Crohn’s and Colitis Who gets IBD.

Page  2 Accutane, a medication used to treat acne, has recently been linked to dangerous health conditions such as inflammatory bowel disease (IBD).

A personal journey through IBD

A capacity building programme for patient representatives

Fabio V. Teixeira, MD, MSc, PhD

Ulcerative colitis andTrichuris infection

High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference Airi Jussila, Lauri J. Virta, Veikko Salomaa,

Work disability in inflammatory bowel disease

PATIENT ACTIVATION IN INFLAMMATORY BOWEL DISEASE PATIENTS

The Nurse’s Role in Inflammatory Bowel Disease

The risk of lymphoma and immunomodulators in patients with inflammatory bowel diseases: Results from a population-based cohort in Eastern Europe Peter.

IBD in the elderly population: Results from a population-based study in Western Hungary, 1977��2008 Peter Laszlo Lakatos, Gyula David, Tunde Pandur,

Ulcerative Colitis (UC)-Associated Colorectal Cancer (CRC) Patients Who Receives Colorectal Surgery More Likely Receive Blood Transfusion Than Crohn’s.

Indeterminate and inconclusive results are common when using Interferon Gamma Release Assay as screening for TB in patients with IBD Nasr I, Goel RM, Ward.

Lung cancer prevalence on the rise (Nov. 2014)

Small bowel Crohn disease.

YouTube® and inflammatory bowel disease

Digestive system Made by: Lexus Batton.

Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: A meta-analysis Vincent Billioud, Alexander C. Ford,

High and increasing prevalence of inflammatory bowel disease in Finland with a clear North–South difference Airi Jussila, Lauri J. Virta, Veikko Salomaa,

Prevalence of irritable bowel syndrome (IBS) in first-degree relatives of patients with inflammatory bowel disease (IBD) Mariam Aguas, Vicente Garrigues,

Medical management of inflammatory bowel disease

Health Care and Research

1 Patient enrollment flow chart.

Figure 3. Proposed algorithm of treatment for patients with a diagnosis of PI [prepouch ileitis]. From: Prepouch Ileitis After Ileal Pouch-anal Anastomosis:

Clinical Correlates of Mental Health Issues in Outpatients with Inflammatory Bowel Disease under Routine Care Taryn Lores Health Psychologist, IBD Service.

Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population- based cohort followed for ten years May-Bente Bengtson, Camilla.

Module 4: Colorectal Cancer

IBD Therapies: Guidance for Managed Care Professionals

جامعة الملك عبد العزيز كلية الاعمال رابغ

Pregnancy in Primary Sclerosing Cholangitis

Reply Gastroenterology

Managing IBD in Children

Diagnosis of celiac sprue

Covering the Cover Gastroenterology

Volume 147, Issue 4, Pages e7 (October 2014)

Trends in Overall and Cause-Specific Mortality Among Patients With Inflammatory Bowel Disease From 1982 to 2010 Tine Jess, Morten Frisch, Jacob Simonsen

Osteoporosis in inflammatory bowel disease

Volume 131, Issue 3, Pages (September 2006)

Reply Gastroenterology

Subrata Ghosh, Benjamin Pariente, Diane R

Volume 152, Issue 1, Pages (January 2017)

Health-related quality of life in inflammatory bowel disease: Psychosocial, clinical, socioeconomic, and demographic predictors Anilga Moradkhani, Linda.

EUROPEAN UNION AND HOSPITALS

Crohn’s disease Austin Edson 6th hour.

Figure 1 Approximate timeline contrasting major historical events in the understanding of ulcerative colitis (red) and ... Figure 1 Approximate timeline.

Eligibility criteria for inclusion as an expert Delphi panellist

Rectal Mucosal Nitric Oxide in Differentiation of Inflammatory Bowel Disease and Irritable Bowel Syndrome Claudia I. Reinders, Max Herulf, Tryggve Ljung,

Volume 140, Issue 6, Pages e2 (May 2011)

Meenakshi Bewtra, Chinyu Su, James D. Lewis

Inflammatory Bowel Disease (IBD)

Volume 152, Issue 8, Pages (June 2017)

Medical Students Working in Multidisciplinary Teams

Cox regression analysis of the proportion of patients remaining in remission during azathioprine treatment related to diagnosis of inflammatory bowel disease.

Treating Inflammatory Bowel Disease With Diet: A Taste Test

Cox regression analysis of the proportion of patients remaining in remission after stopping azathioprine treatment related to diagnosis of inflammatory.

Global Specialty Pharmaceuticals Market. Report Description and Highlights According to Renub Research report "Specialty Pharmaceuticals Market, by Country.

Trivedi C, Shah Y, Khan N Slides compiled by Dr. Michael Stewart

Thiopurines and Risk of Colorectal Neoplasia in Patients With Inflammatory Bowel Disease: A Meta-analysis Tine Jess, Anthony Lopez, Mikael Andersson,

Presentation transcript:

Research and Healthcare in Inflammatory Bowel Diseases (1) What can the European Union and the United European Gastroenterology contribute? rstockbrugger636@gmail.com

Research and Healthcare in Inflammatory Bowel Diseases (2) The causes of these diseases are in principle unknown Incidence of Ulcerative Colitis relatively stable Incidence of Crohn’s Disease rising A number of genetic risk factors identified in Europe Will we be able to contribute to individualised management of IBDs? rstockbrugger636@gmail.com

Research and Healthcare in Inflammatory Bowel Diseases (3) Therapy for IBDs: more has to come! The important new therapies in IBD are invented in the US and in Asia Many of these are tested in Europe because of the good organisation and generally high quality of healthcare However, Europe pays high prices for the ready products Outstanding European researchers leave for research in non-European countries rstockbrugger636@gmail.com

EU helps a lot!

EC-IBD: 1996-2000

Research and Healthcare in Inflammatory Bowel Diseases (4) Care delivery for IBDs In IBDs, Quality of Life depends on Quality of Care IBD care has to cover all components of individual and social life, not only medical diagnosis, treatment and follow-up Access to centralised high quality care normalises mortality in IBDs New disease-adapted care models should be developed, including distant modality ways of diagnosis and treatment as well as multi-professional care-taking rstockbrugger636@gmail.com

Research and Healthcare in Inflammatory Bowel Diseases (5) UEG, ECCO and EFCCA go for a WRITTEN DECLARATION in the EUROPEAN PARLIAMENT Inflammatory Bowel Diseases: “A lifelong craving for health and well-being” rstockbrugger636@gmail.com

rstockbrugger636@gmail.com

rstockbrugger636@gmail.com

rstockbrugger636@gmail.com